Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OncoCAIX
- Development stage
- Unknown
- Lead developer
- Philogen
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
OncoCAIX is a small molecule targeting agent developed by Philogen that specifically binds to Carbonic Anhydrase IX (CAIX), a cell-surface enzyme that is highly overexpressed in clear cell renal cell carcinoma (ccRCC) and other solid tumors under hypoxic conditions. As part of Philogen's 'Onco' platform of small molecule ligands, OncoCAIX is designed to deliver payloads, such as radionuclides for imaging (e.g., Gallium-68) or therapy (e.g., Lutetium-177), directly to the tumor site. This targeted approach aims to improve diagnostic accuracy and therapeutic efficacy while reducing systemic toxicity. The drug is currently in Phase 1 clinical trials for the treatment and imaging of patients with renal cell carcinoma.
- Other names
- CAIX-targeting small molecule
02
Targets
CA9 (Carbonic anhydrase IX)
Beyond the preview
Go deeper on OncoCAIX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OncoCAIX.